Zymeworks (ZYME) Enterprise Value (2021 - 2026)
Zymeworks (ZYME) reported Enterprise Value of -$364.7 million for Q1 2026, down 37.48% on a YoY basis from -$583.4 million in Q1 2025, and down 59.41% sequentially from -$228.8 million in Q4 2025.
Zymeworks (ZYME) Enterprise Value (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Enterprise Value data on file, last reported at -$364.7 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 37.48% year-over-year to -$364.7 million; the trailing twelve-month figure through Mar 2026 stood at -$364.7 million (down 37.48% YoY), and the FY2025 full-year result was -$228.8 million, down 1.34% from the prior year.
- Enterprise Value eased to -$364.7 million in Q1 2026, from -$228.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$166.2 million in Q3 2022 to a low of -$492.2 million in Q4 2022.
- A 5-year average of -$306.6 million and a median of -$297.2 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value slumped 94.86% in 2022 and surged 39.68% in 2024, its largest moves.
- Tracing ZYME's Enterprise Value over 5 years: stood at -$492.2 million in 2022, then rose by 23.95% to -$374.3 million in 2023, then soared by 39.68% to -$225.8 million in 2024, then dropped by 1.34% to -$228.8 million in 2025, then sank by 59.41% to -$364.7 million in 2026.
- Business Quant data shows ZYME's Enterprise Value at -$364.7 million in Q1 2026, -$228.8 million in Q4 2025, and -$251.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Zymeworks | 1.70 Bn | 1.34 Bn | - | -364.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -364.73 Mn |
| Dec 31, 2025 | -228.80 Mn |
| Sep 30, 2025 | -251.93 Mn |
| Jun 30, 2025 | -281.38 Mn |
| Mar 31, 2025 | -265.29 Mn |
| Dec 31, 2024 | -225.78 Mn |
| Sep 30, 2024 | -297.20 Mn |
| Jun 30, 2024 | -330.15 Mn |
| Mar 31, 2024 | -345.05 Mn |
| Dec 31, 2023 | -374.33 Mn |
| Sep 30, 2023 | -295.41 Mn |
| Jun 30, 2023 | -340.09 Mn |
| Mar 31, 2023 | -340.79 Mn |
| Dec 31, 2022 | -492.23 Mn |
| Sep 30, 2022 | -166.24 Mn |
| Dec 31, 2021 | -252.61 Mn |